Product Details

Liquid Biopsy Market - Global Forecast to 2022

Liquid Biopsy market By Cancer Type (Lung, Breast, Colorectal, Prostate), Circulating Biomarkers (Circulating Tumor Cells, Circulating Tumor DNA, Cell-Free DNA), Product (Instruments, Assay Kits), End User (Reference Laboratory) and Geography 

The global liquid biopsy market is projected to be valued at USD XX Billion in 2016 and is expected to grow at a CAGR of XX% to reach to USD XX Billion by 2022. Base year considered for the report is 2016 and forecast period includes 2017–2022. Some of the key factors driving the growth of this market include increasing prevalence of cancer, increasing preference for noninvasive procedures, and availability of funding for liquid biopsy R&D.

  • To define, describe, and forecast the Liquid Biopsy market segmented on the basis of application, technology, types, service, and geography
  • To forecast the market size in terms of value for various segments with respect to four main regions: North America, Europe, APAC, and RoW
  • To provide detailed information regarding the major factors influencing the growth of the Liquid Biopsy market (drivers, restraints, opportunities, and industry-specific challenges)
  • To provide a detailed overview of the value chain in the Liquid Biopsy market and analyze the market trends with Porter’s five forces analysis
  • To analyze the opportunities in the market for various stakeholders by identifying the high-growth segments of the Liquid Biopsy market
  • To strategically profile the key players and comprehensively analyze their market position in terms of ranking and core competencies, along with detailing the competitive landscape for the market leaders
  • To analyze competitive developments such as new product launches and developments; agreements and contracts; mergers and acquisitions; and expansions in the global Liquid Biopsy market

Scope of the Report:

The research report categorizes the global market into the following segments and subsegments:

Liquid biopsy Market, by Product

  • Assays Kits
  • Instruments
  • Services

Liquid biopsy Market, by Circulating Biomarker

  • Circulating Tumor Cells (CTCs)
  • Circulating Tumor DNA (ctDNA)
  • Cell-Free DNA (cfDNA)
  • Extracellular Vesicles (EVs)
  • Other Circulating Biomarkers*

*Other circulating biomarkers include circulating RNA (ctRNA and cfRNA) and cell-free protein biomarkers.

Liquid biopsy Market, by Clinical Application

  • Early Cancer Screening
  • Therapy Selection
  • Treatment Monitoring
  • Recurrence Monitoring Orthopedics

Liquid biopsy Market, by Application

  • Oncology
    • Lung Cancer
    • Breast Cancer 
    • Colorectal Cancer
    • Prostate Cancer
    • Liver Cancer
    • Other Cancers (bladder cancer, pancreatic cancer, brain and nervous system cancer, ovarian cancer and melanoma)
  • Non-Cancer Application

Liquid biopsy Market, by End User

  • Reference Laboratories 
  • Hospitals and Physician Laboratories
  • Academic and Research Centers
  • Other End Users

Liquid biopsy Market, by Region

  • North America
  • Europe
  • Asia Pacific
  • RoW

Table of Contents

1 Introduction

2 Research Methodology

4 Premium Insights
    4.1 Liquid Biopsy Market: Overview 
    4.2 Global Market, By Clinical Application 
    4.3 Global Market: Geographic Growth Opportunities 
    4.4 Global Market: Established vs Emerging Markets

5 Market Overview
    5.1 Introduction 
    5.2 Market Dynamics 
           5.2.1 Drivers
           5.2.2 Restraint
           5.2.3 Opportunities
           5.2.4 Challenges

6 Liquid Biopsy Market, By Product and Service
    6.1 Introduction 
    6.2 Assay Kits 
    6.3 Instruments 
    6.4 Services

7 Liquid Biopsy Market, By Circulating Biomarker
    7.1 Introduction 
    7.2 Circulating Tumor Cells 
    7.3 Circulating Tumor DNA (CTDNA) 
    7.4 Cell-Free DNA 
    7.5 Extracellular Vesicles (Evs) 
    7.6 Other Circulating Biomarkers

8 Liquid Biopsy Market, By Clinical Application
    8.1 Introduction 
    8.2 Early Cancer Screening 
    8.3 Therapy Selection 
    8.4 Treatment Monitoring 
    8.5 Recurrence Monitoring

9 Liquid Biopsy Market, By Application
    9.1 Introduction 
    9.2 Cancer Applications 
           9.2.1 Lung Cancer
           9.2.2 Breast Cancer
           9.2.3 Colorectal Cancer
           9.2.4 Prostate Cancer
           9.2.5 Liver Cancer
           9.2.6 Other Cancers
    9.3 Non-Cancer Applications

10 Liquid Biopsy Market, By End User
     10.1 Introduction 
     10.2 Reference Laboratories 
     10.3 Hospitals and Physician Laboratories 
     10.4 Academic and Research Centers 
     10.5 Other End Users

11 Liquid Biopsy Market, By Region
     11.1 Introduction 
     11.2 North America 
     11.3 Europe 
     11.4 Asia Pacific 

     11.5 Rest of the World (RoW)

12 Competitive Landscape

13 Company Profiles
(Overview, Products Offered, Strength of Product Portfolio, Business Strategy Excellence, Recent Developments.)*
     13.1 Biocept, Inc. 
     13.2 Qiagen N.V. 
     13.3 Roche Diagnostics 
     13.4 Bio-Rad Laboratories, Inc. 
     13.5 Myriad Genetics, Inc 
     13.6 Menarini-Silicon Biosystems 
     13.7 Trovagene, Inc. 
     13.8 Guardant Health, Inc. 
     13.9 Mdxhealth SA 
     13.10 Genomic Health, Inc. 
     13.11 Raindance Technologies, Inc 
     13.12 Thermo Fisher Scientific Inc. 
     13.13 Illumina, Inc.

*Details on Overview, Strength of Product Portfolio, Business Strategy Excellence, Recent Developments, Key Relationships Might Not Be Captured in Case of Unlisted Companies.


Single User   1560.00

Multiple User   2700.00
Latest Product